Tyrosine kinases in inflammatory dermatologic disease.
Tyrosine kinases (TKs) are enzymes that catalyze the phosphorylation of tyrosine residues on protein substrates. They are key components of signaling pathways that drive an array of cellular responses including proliferation, differentiation, migration, and survival. Specific TKs have recently been identified as critical to the pathogenesis of several autoimmune and inflammatory diseases. Small-molecule inhibitors of TKs are emerging as a novel class of therapy that may provide benefit in certain patient subsets. In this review, we highlight TK signaling implicated in inflammatory dermatologic diseases, evaluate strategies aimed at inhibiting these aberrant signaling pathways, and discuss prospects for future drug development.
Paniagua
Ricardo T
RT
Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, California; Geriatric Research Education and Clinical Center, Palo Alto Department of Veterans Affairs Health Care System, Palo Alto, California.
Fiorentino
David F
DF
Department of Dermatology, Stanford University School of Medicine, Stanford, California.
Chung
Lorinda
L
Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, California; Geriatric Research Education and Clinical Center, Palo Alto Department of Veterans Affairs Health Care System, Palo Alto, California.
Robinson
William H
WH
Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, California; Geriatric Research Education and Clinical Center, Palo Alto Department of Veterans Affairs Health Care System, Palo Alto, California. Electronic address: wrobins@stanford.edu.
D015415:Biomarkers / Q000378:metabolism; D003872:Dermatitis / Q000188:drug therapy* / Q000201:enzymology* / Q000503:physiopathology; D003882:Dermatomyositis / Q000188:drug therapy / Q000201:enzymology / Q000503:physiopathology; D016503:Drug Delivery Systems; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D010766:Phosphorylation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000378:metabolism*; D018570:Risk Assessment; D012595:Scleroderma, Systemic / Q000188:drug therapy / Q000201:enzymology / Q000503:physiopathology; D015398:Signal Transduction; D016896:Treatment Outcome
D015415:Biomarkers; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases